Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...

“In a hypothetical health plan covering 1 million lives, adding biosimilar denosumab to a health plan formulary may contribute to significant cost savings; savings can be reinvested to further expand ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

Samsung Bioepis launches denosumab biosimilars, Obodence and Xbryk in Europe: Incheon, Korea Tuesday, December 2, 2025, 14:00 Hrs [IST] Samsung Bioepis Co., Ltd. announced the lau ...

For Immediate Release Chicago, IL – December 9, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva ...

U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg ...

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY ® ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition ...

Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...